Replies to post #196267 on Amarin Corp Plc (AMRN)

[RobinF]

Do you know what RWE is? Can’t argue with it. FDA knows that.

[biowreck]

Because no one cares. Might as well put your story next to the national inquirer, or town crier at the grocery store checkout stand...lol

[Mercator21]

MRC, I believe the price action since your report is refuting pretty much everything you have written. If your opinion based report was anything to be concerned about, the stock would be back to low single digits, FDA would have requested additional data by now and would have not accepted the sNDA assigning priority review. I found your timing of release interesting.

If I would be at a hedge fund and we would have such a strong bearish opinion on a stock as you have, and we would make it public (maybe you are trying to copy Citron BP) and the market would yawn at the report, as it did, we wouldn’t be pounding our chests but go back to the drawing board and try to figure out what we missed.

So if I would agree with your bearish opinion, I would first evaluate the big picture since I (or you) really don’t have all the necessary data to change an opinion to a fact.

Therefore, I would have to believe that:
1. AMRN management is a fraud and will be going to jail
2. Dr. Bhatt and all the other experts/associations endorsing this data are unable to interpret the data as well as you, who doesn’t have all the data.
3. FDA accepted the sNDA and granted priority review only to turn down the application (wouldn’t they at least request additional data prior to acceptance, especially with the history between AMRN and FDA)
4. Baker Brothers are unable to understand the data as well as you
5. The script growth over the last 7 years was all fake news and patients and doctors have not seen any benefits throughout these years
6. R-IT was a scam
7. The USPTO just giving out patents like candy to anyone who asks (from my own due diligence in the past, AMRN’s patents were highly scrutinized by the USPTO and I am very comfortable about them holding up in court).

I could go on and on but you get the point.

Again, it’s a report based on your opinion (and I have heard most of these opinions over the last 8+ years, especially from the Omthera management) and without the access to all the required data, it is just one opinion vs another and that’s what makes a market. The beauty here is that we will find out this year, whose opinion is closer to the truth. In my opinion, you will be proven wrong again.